A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

Condition studied

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility

Primary endpoint

Adverse events, laboratory assessments. Assessments related to adverse events include: • Occurrence/frequency • Relationship to IMP as assessed by Investigator • Intensity • Seriousness • Death • Adverse events leading to discontinuation of IMP • Other significant AEs